内克塔治疗 NKTR 深 沪
交易中 08-13 11:47:19 美东时间
24.2302
+0.630
+2.67%
华盛通- 最 高24.49
- 今 开23.88
- 成交量 19.72万股
- 最 低 23.675
- 昨 收 23.60
- 总市值 3.01亿
- 52周最高 37.38
- 市盈率 静 --
- 换手率 1.59%
- 52周最低 6.48
- 委 比 88.68%
- 总股本 1240.69万
- 历史最高 1670.40
- 量 比 0.96
- 振 幅 3.45%
- 历史最低 6.189
- 每 手 1
- 风险率 4.97%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
08-11 00:20
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered NK cell therapies, will participate in the H.C. Wainwright "HCW@Home" Series. The event will feature a fireside chat on July 30, 2025, at 11:00 a.m. ET, and registration is available via the provided link. Nkarta is advancing allogeneic NK cell therapies for autoimmune diseases using cell engineering and genome-editing technologies. The company aims to develop accessib...
07-23 12:01
美股大行评级 | 潜在涨幅687%！ 花旗上调新氧科技目标价升至5.5美元，评级"买入"
今日重点评级关注：B. Riley证券：维持内克塔治疗"买入"评级，目标价从60美元升至85美元；Oppenheimer：维持Praxis Precision Medicine"跑赢大市"评级，目标价从97美元升至115美元
07-09 09:26
B. Riley Securities Maintains Buy on Nektar Therapeutics, Raises Price Target to $85
B. Riley Securities analyst Mayank Mamtani maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $60 to $85.
07-09 01:58
Nektar Therapeutics Prices Underwritten Public Offering Of $100M Of Shares At $23.50/Shr
Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its underwritten public offering
07-01 19:19
MSC Industrial Direct, Constellation Brands And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading higher this morning on Tuesday, some of the sto...
07-01 15:09
Nektar Therapeutics launches proposed public offering
Nektar Therapeutics (NASDAQ:NKTR) has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase shares of its common stock. NKTR -2.45% after hours to...
07-01 04:10
Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of imm...
07-01 04:02
